Renal Disease

Disease State Hub

Pearls of Wisdom

Clinical Pearls

Clinical Pearls

Demystifying Resistant Hypertension: Practice Pearls for the Outpatient Clinician

09/14/2026

Anand Ravindran, MD

Although blood pressure (BP) can be controlled with standard treatment regimens in many patients, achieving or maintaining BP control is particularly challenging in patients with resistant hypertension. ...

09/14/2026

Research Summaries

Timelines

Notable FDA Approvals in July

07/27/2026

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

07/27/2026

Research Summary

Research Summary

Cefazolin Noninferior to Flucloxacillin/Cloxacillin for 90-Day Mortality in Adult MSSA Bacteremia

06/30/2026

Anthony Calabro, MA

In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...

06/30/2026

Timeline Snapshot

Notable FDA Approvals in June

06/29/2026

June 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

06/29/2026

FDA Approval

FDA Approval

FDA Approves Belzutifan (Welireg) Plus Pembrolizumab (Keytruda) for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

06/25/2026

Anthony Calabro, MA

The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...

06/25/2026

ASCO CONFERENCE COVERAGE

ASCO CONFERENCE COVERAGE

GLP-1RA Use Associated With Lower Metastatic Progression in Propensity-Matched Solid Tumor Analysis

05/22/2026

Anthony Calabro, MA

In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...

05/22/2026

October 2026

Current Issue

October 2026